MedTrace Logo

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants

NCT06356259 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2025-03-26

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics with intravenous(IV) administration of IRX-010 in Healthy Participants.

Conditions

  • Healthy Participants

Interventions

DRUG

IRX-010

Administered IV

DRUG

Placebo

Administered IV

Sponsors & Collaborators

  • ImmunoRx Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • ImmunoRx Pharma,Inc · ImmunoRx Pharma Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-07
Primary Completion
2025-01-23
Completion
2025-01-23

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06356259 on ClinicalTrials.gov